Bortezomib is an injectable generic chemotherapy drug developed for the treatment of multiple myeloma and other indications. Currently there is no marketed generic for this product and the brand generates annual revenues of over $800 million USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
We're here to help!
Click the close icon to dismiss the modal and open it again to have some fun with it
